Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) EBIT (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBIT for 8 consecutive years, with -$19.5 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 45.72% to -$19.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$108.5 million, a 63.78% decrease, with the full-year FY2024 number at -$67.5 million, up 6.22% from a year prior.
  • EBIT was -$19.5 million for Q3 2025 at Whitehawk Therapeutics, up from -$54.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$3.9 million in Q2 2021 to a low of -$86.9 million in Q3 2021.
  • A 5-year average of -$21.2 million and a median of -$16.8 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 1383.11% in 2021, then soared 82.7% in 2022.
  • Whitehawk Therapeutics' EBIT stood at -$15.9 million in 2021, then increased by 2.97% to -$15.5 million in 2022, then fell by 14.49% to -$17.7 million in 2023, then fell by 6.97% to -$18.9 million in 2024, then fell by 3.15% to -$19.5 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's EBIT are -$19.5 million (Q3 2025), -$54.7 million (Q2 2025), and -$15.2 million (Q1 2025).